Understanding Uterine Cancer: Causes, Risk Factors, and Early Warning Signs
Most conversations about uterine cancer jump straight to screening protocols or treatment options. That skips the most important step of all — understanding why it develops in the first place. When patients and clinicians understand the underlying mechanisms driving uterine cancer, the decisions that follow become sharper, faster, and more effective. Who is genuinely at risk? Which symptoms demand swift investigation? Where is prevention most realistic? This guide answers all three questions, mechanism first, and translates the biology into practical decisions that can be acted upon immediately. For personalised assessment, the Gynaecology and Oncology specialists at Moolchand Hospital are available for expert consultation.
The Primary Driver: Unopposed Oestrogen
The central biological mechanism behind the most common form of uterine cancer — Type 1 endometrial cancer — is unopposed oestrogen. In straightforward terms, this means oestrogen stimulating the endometrium (the lining of the uterus) without sufficient progesterone to counterbalance the resulting cell proliferation. Over repeated cycles, this imbalance can produce endometrial hyperplasia, which may progress to malignancy. Type 1 tumours linked to oestrogen stimulation account for approximately 80% of all uterine cancer cases — a figure that immediately clarifies why hormonal balance sits at the centre of both prevention and risk assessment.
The most common sources of unopposed oestrogen include anovulatory cycles, perimenopausal periods of irregular ovulation, obesity-driven peripheral conversion of androgens to oestrogens, and oestrogen-only hormone replacement therapy in women who still have a uterus. The protective counterweight in each case is adequate progesterone — either from natural ovulation or from prescribed progestogen in combined hormone therapy regimens.
This biology is not abstract. It is, essentially, the monthly hormonal pattern repeated over years. Risk accumulates from prolonged stimulation without adequate cellular differentiation — which is precisely why early identification and intervention matters so much.
Obesity and Metabolic Syndrome
Obesity is the single most modifiable contributor to uterine cancer risk. Adipose tissue converts androgens to oestrogens through a process called aromatisation, raising baseline oestrogen exposure significantly. Obesity also drives hyperinsulinaemia and chronic low-grade inflammation — conditions that create a cellular microenvironment favouring uncontrolled proliferation. Research indicates that obesity accounts for more than half of all endometrial cancer cases. The relationship is dose-responsive: higher BMI generally confers higher risk.
Metabolic syndrome — the cluster of obesity, insulin resistance, hypertension, and dyslipidaemia — compounds this risk through multiple simultaneous pathways. Insulin and IGF signalling reduce programmed cell death and promote tumour growth. Systemic inflammation adds further biological pressure. The practical implication is significant: because these factors are modifiable, addressing them directly reduces cancer risk alongside cardiovascular and metabolic disease.
Practical interventions include gradual weight loss of 5–10%, structured aerobic and resistance exercise, dietary reduction of ultra-processed foods and added sugars, and — where clinically indicated — metformin for insulin resistance. The Endocrinology and Metabolic Health team at Moolchand Hospital works alongside gynaecology specialists to address these intersecting risks within a single coordinated care plan.
Genetic Mutations and Hereditary Syndromes
Not all uterine cancers arise from hormonal and metabolic pathways. A meaningful proportion are driven by inherited genetic mutations. Lynch syndrome — caused by mismatch repair gene mutations — markedly raises lifetime risk of endometrial cancer. Cowden syndrome, resulting from PTEN mutations, similarly increases susceptibility. These pathways operate upstream of hormonal effects and can produce disease at younger ages than the typical presentation.
Key indicators of possible hereditary risk include a strong family history of both colorectal and endometrial cancers, early-onset uterine cancer, or a personal history of multiple primary tumours. Where these features are present, formal genetic counselling and targeted testing are appropriate. Surveillance protocols and risk-reducing interventions — including prophylactic surgery in selected cases — can then be planned with precision. Genetics does not override hormonal and metabolic factors; it intersects with them, and the net result is cumulative risk that can partly be anticipated and managed through proactive screening.
Medication-Related Risk Factors
Two medication classes require careful attention in any discussion of uterine cancer risk. First, hormone replacement therapy: oestrogen-only therapy in women who have a uterus raises endometrial cancer risk. Combined oestrogen-progestogen regimens substantially mitigate this risk by opposing endometrial proliferation. The choice of regimen matters, and it should be reviewed regularly against evolving clinical evidence.
Second, tamoxifen — used in breast cancer management — has partial oestrogen agonist effects on the endometrium. Long-term use is associated with increased endometrial cancer risk. Women on tamoxifen who experience any vaginal bleeding should have a low threshold for endometrial assessment. Protective alternatives, including the levonorgestrel intrauterine system, can provide endometrial protection while maintaining treatment benefit in appropriate candidates. The Oncology team at Moolchand Hospital regularly reviews long-term medication risk profiles as part of integrated cancer risk management.
Major Risk Factors at a Glance
Age and Menopause Status
Risk increases with age and is highest after menopause. The clinical rule is reliable: any vaginal bleeding in a postmenopausal woman warrants prompt investigation until proven otherwise. Before menopause, patterns matter more than isolated episodes — persistent intermenstrual bleeding, heavily irregular cycles, or very long gaps between periods all signal anovulatory oestrogen exposure that warrants evaluation.
Reproductive History
Early menarche and late menopause extend lifetime oestrogen exposure. Nulliparity removes the relatively progesterone-dominant periods of pregnancy. Infertility related to chronic anovulation compounds risk further. These historical factors are not adjustable, but they are valuable for accurate risk stratification and for guiding the threshold at which new symptoms should be investigated.
Associated Medical Conditions
Polycystic ovary syndrome (PCOS), type 2 diabetes, insulin resistance, and hypertension all intensify the same hormonal and metabolic pathways already described. Women with PCOS, in particular, experience repeated cycles of unopposed oestrogen due to chronic anovulation. Proactive cycle regulation and endometrial protection with progestogen are both clinically appropriate and risk-reducing in this group.
Lifestyle and Environmental Factors
Diet quality, physical activity, and environmental exposures all influence background risk. Sustained moderate-to-vigorous physical activity lowers risk through weight management, insulin sensitivity, and anti-inflammatory effects. Research has also identified outdoor air pollution — specifically elevated nitrogen dioxide levels — as an environmental modifier linked to higher uterine cancer incidence. Practical responses include active commuting where safe, indoor air filtration during high-pollution periods, and consistent dietary quality improvements prioritising fibre, plant diversity, and reduced ultra-processed food intake.
Recognising the Warning Signs
Abnormal Bleeding
Bleeding patterns offer the clearest and most consistent early signal of uterine pathology. For postmenopausal women, any vaginal bleeding is clinically significant and requires investigation. For premenopausal women, the following patterns warrant prompt review:
- Intermenstrual bleeding or spotting, particularly if persistent or recurrent
- Periods that have become significantly heavier or longer without clear cause
- Bleeding after sexual intercourse
- Very irregular cycles with prolonged gaps, suggesting anovulatory oestrogen exposure
These bleeding changes overlap with many benign conditions. Even so, they represent the most direct clinical window into the underlying mechanisms driving uterine cancer risk, and a structured early evaluation consistently produces better outcomes than delayed investigation.
Non-Bleeding Symptoms
Pelvic pressure or discomfort that does not resolve, a new watery or lightly blood-tinged vaginal discharge, and pain during intercourse may all accompany uterine pathology. On their own, these symptoms are less specific — but in the context of abnormal bleeding or a high-risk history, they add meaningful clinical weight and should not be dismissed.
Signs of Advanced Disease
Unintentional weight loss, persistent fatigue, changes in bowel or urinary habits, and sustained pelvic or back pain may indicate more advanced disease with local or distant spread. Leg swelling can reflect lymphatic involvement. These features signal urgency and the need for comprehensive imaging and biopsy without delay.
When to Seek Medical Attention
The threshold for investigation should be low. Seek prompt evaluation at Moolchand Hospital's Gynaecology Department for any of the following:
- Postmenopausal vaginal bleeding of any volume
- Persistent intermenstrual bleeding or post-coital bleeding
- New abnormal bleeding in the context of PCOS, obesity, diabetes, or a relevant family history
The standard assessment pathway includes pelvic examination, transvaginal ultrasound to assess endometrial thickness, and endometrial biopsy where indicated. Hysteroscopy with directed sampling follows if initial investigations are inconclusive. Earlier detection almost always permits curative surgery with less intensive adjuvant treatment. Documenting the timing, volume, and any associated symptoms before the appointment significantly shortens the diagnostic process.
A Practical Prevention Framework
Understanding the mechanisms driving uterine cancer transforms concern into concrete, achievable steps. The five most impactful actions are:
- Protect the endometrium — Use cyclical progestogen or a levonorgestrel IUS in women with anovulatory cycles or long-term oestrogen exposure
- Optimise metabolic health — Work towards a realistic weight trajectory, address insulin resistance, and build regular physical activity into the week
- Review medications — Avoid oestrogen-only therapy in women with a uterus; reassess long-term tamoxifen use where risk-benefit has shifted
- Investigate bleeding promptly — Treat postmenopausal bleeding as urgent; do not watch and wait through repeated episodes
- Address family risk — Pursue genetic assessment where Lynch syndrome or related conditions are plausible; plan surveillance accordingly
For dietary habits, the principle is pattern over perfection. Reduce ultra-processed foods and added sugars. Increase fibre, legumes, and vegetables. Aim for strength training twice weekly and moderate aerobic activity on most days. These changes move multiple risk markers simultaneously and reduce far more than uterine cancer risk alone.
Awareness of uterine cancer causes should not produce anxiety — it should produce clarity. Speak to a clinician early when symptoms appear, then act with a calm and methodical plan. Book an appointment with Moolchand Hospital's specialist team to begin that conversation today.
The Cancer Care and Gynaecology specialists at Moolchand Hospital, New Delhi provide integrated, evidence-based assessment and management for women at risk of or diagnosed with uterine cancer. Early review saves lives.
